Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane | CAS:78560-44-8

We serve Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane CAS:78560-44-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane

Chemical Name:Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane
CAS.NO:78560-44-8
Synonyms:Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane;
Molecular Formula:C10H4Cl3F17Si
Molecular Weight:581.55600
 
Physical and Chemical Properties:
Density:1.7146;
Boiling point:90oC;
Melting point:10.87oC;
Index of Refraction:1.349;
 
Specification:
Appearance: Colorless to light red liquid
Assay :≥97.0%



Contact us for information like Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane Use and application,Trichloro(1H,1H,2H,2H-heptadecafluorodecyl)silane technical grade,usp/ep/jp grade.


Related News: The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.1-Bromopyrene manufacturer Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days.2,6-Dichloro-4-nitrophenol supplier The Shanghai Institute of Materia Medica is under the Chinese Academy of Sciences (CAS), a top government think tank. The Wuhan Institute of Virology is also administered by the CAS and is among the country’s most advanced virus research laboratories.Phenylboronic acid vendor In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.”Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself.”